Cloverleaf Bio, a New Haven, CT-based provider of engineered transfer RNA (tRNA) based payloads for cancer, raised $33M in Seed funding. The round was led by 4BIO Capital with participation from AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge....See more